Vaxxas partners with AI company Profenso to support quality assurance

A strategic partnership between Vaxxas and Profenso, an Australian artificial intelligence company specialising in advanced automation for regulated industries, has been announced. The partnership is to develop a next-generation AI vision capability to support quality assurance during high-speed manufacturing of Vaxxas’s high-density microarray patch (HD-MAP) technology for vaccination.

Manufactured in an aseptic (sterile) environment, the HD-MAP technology requires precise, stringent controls to ensure every patch meets safety and performance standards — the integration of Profenso’s AI vision technology into Vaxxas’s production workflows aims to introduce real-time insights, automated quality evaluation and improved traceability across critical manufacturing steps.

“Manufacturing HD-MAP vaccines requires precision at a scale that few technologies demand,” said Dr Maciej Trzaskowski, Co-Founder and Managing Director of Profenso. “AI vision systems add value by augmenting human oversight, reducing variability and giving teams richer insight into the production quality essential for highly regulated industries. It’s exciting to be collaborating with Vaxxas on this project to create purpose-built technology that can elevate manufacturing quality on a global scale.”

Profenso will build and train a bespoke AI vision platform — engineered for microscopic-scale quality assurance — as part of the project. The solution will be engineered to combine advanced imaging, agentic architecture and structured quality workflows that integrate with Vaxxas manufacturing controls.

“Ensuring the highest level of manufacturing quality is central to delivering on the promise of HD-MAP technology. Working with Profenso gives us access to leading edge AI innovation tailored for regulated production environments,” said Dr Scott Fry, Chief Operating Officer at Vaxxas. “Their approach to automated vision analysis will help to strengthen our existing quality processes and support our expansion to larger-scale manufacturing.”

Progressing through phased development, with early testing focused on automated classification, surface analysis and microstructure verification, later stages of the partnership will explore integration into broader quality management for manufacturing and alignment with future regulatory requirements.

Image credit: iStock.com/Chainarong Prasertthai